MDCX vs VENU โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MDCX Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Medicus Pharma Ltd. Common Stock (MDCX) driven by superior Growth & Margin, Momentum & Technical while VENU counters with relative strength in Options & Structure. Fundamentally, MDCX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus VENU at N/M Forward P/E and -294.7% operating margin (+2.9% YoY). In options structure, MDCX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against VENU sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MDCX | VENU | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.1M | $58.3M | Larger Scale | VENU |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +2.9% | Higher Growth | VENU |
| Operating Margin (TTM) Profitability | 0.0% | -294.7% | Higher Margin | MDCX |
| Net Profit Margin Profitability | 0.0% | -281.4% | Higher Margin | MDCX |
| Return on Equity (ROE) Capital Efficiency | -7446.1% | -24.9% | Higher ROE | VENU |
| 52-Week Range Position Momentum | 23% ($0โ$5) | 1% ($1โ$11) | Stronger Trend | MDCX |
| Beta / 30D Volatility Risk Regime | -0.28ฮฒ ยท 118% Vol | 1.72ฮฒ ยท 86% Vol | Lower Realized Risk | VENU |
| Unified Institutional Score Composite Signal | 49.2 / 100 (HOLD) | 42.3 / 100 (HOLD) | Higher Composite | MDCX |